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SLC6A4The known Gly56Ala mutation in the serotonin transporter SERT (or 5-HTT), encoded by the SLC6A4 gene,
causes increased serotonin reuptake and has been associated with autism and rigid–compulsive behavior. We
report a patient with macrocephaly from birth, followed by hypotonia, developmental delay, ataxia and a
diagnosis of atypical autism (PDD-NOS) in retrospect at the age of 4½years. Low levels of the serotonin end-
metabolite 5-hydroxyindolacetic acid (5HIAA) in CSF were detected, and SLC6A4 gene analysis revealed the
heterozygous Gly56Ala alteration and the homozygous 5-HTTLPR L/L promoter variant. These changes are
reported to be responsible for elevated SERT activity and expression, suggesting that these alterations were
responsible in our patient for low serotonin turnover in the central nervous system (CNS). Daily treatment
with 5-hydroxytryptophan (and carbidopa) led to clinical improvement and normalization of 5HIAA,
implying that brain serotonin turnover normalized. We speculate that the mutated 56Ala SERT transporter
with elevated expression and basal activity for serotonin re-uptake is accompanied with serotonin
accumulation within pre-synaptic axons and their vesicles in the CNS, resulting in a steady-state of lowered
serotonin turnover and degradation by monoamine-oxidase (MAO) enzymes in pre-synaptic or neighboring
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Autism is a childhood-onset disorder with neuro-developmental
abnormalities in early life leading to severe defects in social interaction,
communication and limited activitieswith repetitive stereotypic behavior
ormovements [1]. The Autism SpectrumDisorders (ASD) include besides
the “typical” Kanner autism, Asperger's syndrome and the atypical forms
of autism, also known as pervasive developmental disorder — not
otherwise speciﬁed (PDD-NOS). In more than 25–50% of individuals
suffering fromASD and their ﬁrst-degree relatives, whole blood serotonin
levels were found to be elevated due to increased serotonin storage
within platelets [2,3]. In addition, functional neuro-imaging studies using
positron emission tomography (PET) have shown diminished serotonin
synthesis in children with autism between the age of 2 and 5 years, aswell as the focal aberrations of serotonin synthesis and the low binding
potentials of the serotonin transporter and receptor in individuals with
ASD [4,5]. Short-term dietary depletion of tryptophan (i.e. the serotonin
precursor) has been shown to exacerbate repetitive behavior and to
elevate anxiety and feelings of unhappiness in autistic individuals [6]. In
contrast, treatment with selective serotonin re-uptake inhibitors –
commonly used antidepressants – interacts pharmacologically with the
serotonin transporter SERT (or 5-HTT) and has been shown to be
effective in ameliorating the repetitive and/or obsessive behavior and
interests in some but not all autistic individuals [7].
The serotonin transporter SERT or 5-HTT, encoded by the SLC6A4
gene, is thought to play a prominent role in serotonin homeostasis in
primates and non-human primates, and several gene variants that may
change the structure or function of the transporter protein were
associated with autism [8]. Among them, polymorphisms within the 5-
HTTLPR promoter sequence, mutations in the coding sequence, or
intronic mutations of this serotonin transporter were reported to be
linked to autism by some studies, but other studies have been
inconclusive [8–10]. The SLC6A4 5-HTTLPR promoter sequence, located
about 1 kb upstream of the transcription initiation site, contains two
variable repeat length polymorphisms known as the long (L) with 16
repeat elements, or the 44 bp shorter (S) variant with 14 repeat
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serotonin transporter in pre-synaptic axonic membranes. The L/L
genotype of this 5-HTTLPR promoter variant expresses signiﬁcantly
(1.4–1.5 fold) more transporter protein as compared to the L/S or S/S
variants [13]. As a consequence, the L/L variant was proposed to lead to
a lowered concentration of serotonin in the synaptic cleft, although
contradictory reports regarding the role of 5-HTTLPR variations exist
(see e.g. [14]). In addition to these non-coding variants in the promoter
region, a number of mutations in the coding region modulate SERT
activity [10]. Among them, the non-synonymous variant Gly56Ala in
exon 3 of the SLC6A4 gene was reported to be autism-associated and
showed constitutively elevated SERT activity [15]. This glycine to
alanine exchange at position 56 is located in the N-terminal
intracellular tail of the SERT-protein. Pharmacological studies of
serotonin re-uptake by EBV-transformed lymphocytes expressing the
heterozygous Gly56Ala or homozygous 56Ala protein mutants indicat-
ed a progressive gain of function by 1.4 or 1.8 fold, respectively,
compared to cells expressing the wild-type SERT (Gly56) [15]. Another
known variant of the SLC6A4 gene, which potentially modulates
serotonin transport function, is a variable number of tandem repeat
(VNTR) polymorphism in intron 2, STin2.9, STin2.10, and STin2.12,
containing 9, 10 and 12 copies of the VNTR element, respectively [8,16].
The in vitro ﬁndings of increased serotonin re-uptake by the
heterozygous SERT mutation 56Ala by pre-synaptic axons will be
expected to enhance both serotonin recycling into vesicles and
degradation by monoamine-oxidase (MAO) enzymes to the 5HIAA
end-metabolite. 5HIAA measurements in CSF are thought to provide
an accurate and comparable parameter for extra-cellular brain
serotonin levels [17]. However, the adaptive changes with respect to
serotonin autoreceptor expression, release of serotonin and its de
novo synthesis remain unknown. Our report on a patient with atypical
autism and speech delay carrying the heterozygous Gly56Ala allele of
the SLC6A4 gene in combination with the 5-HTTLPR L/L promoter
variant documents for the ﬁrst time ﬁndings of low 5HIAA in CSF and
response to therapeutic intervention with 5-hydroxytryptophan/
carbidopa with clinical improvement and normalization of 5HIAA in
CSF, indicative of normal serotonin turnover in the brain.
2. Subjects and methods
2.1. Case report
This patient described here was reported in a previous paper
(patient CM; number 3; [18]) as a boy from healthy, non-
consanguineous parents, born after an uneventful prenatal period
with a birth weight of 3450 g, 52 cm body length and 38 cm head
circumference. After a normal neonatal period, the boy was described
as a ﬂoppy infant during the ﬁrst months, and his history revealed
macrocephaly at and from birth with hypotonia and moderate delay
of acquisition of motor milestones. He was able to pull himself to
stand at 20 months and started to walk with an ataxic gait from the
age of 2½years. His development was marked by psychomotor
retardation with speech delay and development of a hypotonic–ataxic
syndrome at the age of 3½years. In retrospect, a diagnosis of atypical
autism at the age of 4½years was suspected and could be conﬁrmed
recently as a review of the patient's history. The patient fulﬁlled the
DSM-IV criteria for atypical autism (or PDD-NOS), being at that time
all criteria of qualitative impairment of social interaction (4 items), all
criteria for qualitative impairment in verbal and non-verbal commu-
nication (4 items), but lack of the criteria for restricted repetitive and
stereotyped patterns of behavior, interests and activities, as manifes-
ted by 4 items. Before the age of 4½years, he also had expressive
speech delay as mentioned and did not show symbolic or imaginative
play with severely disrupted social interaction and his condition could
not be better accounted for by other neurological disorders. In
summary, these manifestations comply with atypical autism at theage of 4½years. Other testing like ADOS, ADI-R or CARS has not been
performed at that time.
As mentioned before, the patient has been reported in a previous
paper (patient number 3; [18]), describing ﬁve boys suffering from a
novel neuro-developmental condition with psychomotor delay and a
hypotonic–ataxic syndrome. All ﬁve patients had isolated low 5HIAA
levels in CSF and responded to treatmentwith the serotonin precursor
5-hydroxytryptophan and the peripheral decarboxylase inhibitor
carbidopa. Side-effects have never been reported. Following treat-
ment with 5-hydroxytryptophan from the age of 4½years, the here
presented patient started to improve his motor skills and gait, fell less
frequently and became able to use stairways. Much of improvement of
his motor skills related to diminution of ataxic signs and better muscle
tone. About 4 months after treatment the parents noticed that he
started to utter sounds and attempted to speak single words and tried
to add gestures to communicate to his brother and parents. From the
age of 5½years carbidopa was added to 5-hydroxytryptophan. He
soon started to speak and communicate with interest in social
interaction with his peers and other persons. The parents described as
if he awakened from his ownworld. At the age of 5.9 years he had still
an expressive language disorder and a non-verbal IQ test estimated
his IQ between 80 and 90 [19]. The now nearly 17 year-old boy
continued to receive treatment of 5-hydroxytryptophan and carbi-
dopa from the age of 4 ½years.
Although a central disorder of serotonin synthesis or low serotonin
turnover was suspected, further genetic analysis of the genes encoding
the neuronal and peripheral tryptophan hydroxylase genes was normal.
Extensive investigations were normal, including neurophysiological
studies, neuro-imaging, metabolic and genetic testing.
2.2. Methods
Lumbar puncture was performed according to a ﬁxed protocol
between 8:30 and 10:00 a.m. as described previously for determination
of the biogenic aminemetabolites, pterins and 5-methyltetrahydrofolate
[20,21]. A fasting amino-acid analysis in plasma and CSF was performed
on the patient.
After parental informed consent for the boy, an oral dose of 5-
hydroxytryptophanwas started. At the age of 4½years, the child was put
on a normal diet, excluding tryptophan rich nutrients, and 24-hour
urinary 5HIAA excretion was measured before and after a low testing
dose of 5-hydroxytryptophan at 1 mg/kg/day (tid) after hospital
admission. Simultaneously, clinical tolerability during his stay in hospital
was tested using a regular check-up of his general and neurological status
as well as continuous monitoring of cardiopulmonary and circulatory
parameters. Thereupon, oral treatment by 5-hydroxytryptophan was
slowly increased at biweekly intervals with increments of 0.5 to 1 mg/kg/
day (tid), up to a maximum daily dose of 7 mg/kg (tid) with regular
veriﬁcation of his clinical response and adverse side-effects. During
treatment at this maximum 5-hydroxytryptophan dose, a lumbar
puncture was repeated at the age of 5.2 years to check his spinal ﬂuid
5HIAA levels. As spinal ﬂuid 5HIAA and 5-hydroxytryptophan levels had
remained low, we decided to reduce the 5-hydroxytryptophan dose by
30% to 5 mg/kg/day (tid) and added a low dose of carbidopa at 1 mg/kg/
day (tid) from the age of 5½years. During combined treatment with 5-
hydroxytryptophan and carbidopa a CSF sample was repeated at the age
of 5.9 years.
Genetic analysis included genomic DNA sequence analysis from
various genes (see below). For the SLC6A4 gene, we additionally
investigated the 5-HTTLPR promoter variants and the intronic (intron
2) STin2 VNTR polymorphisms. All exons and exon–intron boundaries
were sequenced from the following genes: tryptophan hydroxylases
type 1 and 2 (TPH1, MIM# 191060, ENST0000250018; TPH2, MIM#
607478, ENST00000333850), GTP cyclohydrolase I feedback regulatory
protein (GCHFR, MIM# 602437, ENST00000260447) and serotonin
transporter (SLC6A4, MIM#182138, ENST00000394821).More detailed
Fig. 1. Detection of the heterozygous variant c.167GNC (p.Gly56Ala) in exon 3 of the
SLC6A4 gene in patient CM with atypical autism. For more details see Methods plus
Supporting information and Table S1.
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5-HTTLPR and STin2 VNTR, is given in “Supporting information” and in
Table S1.
3. Results
The CSF ﬁndings for our patient are depicted in Table 1 (see also
reference [18]). The only aberrant baseline value for the metabolites
analyzed was the lowered 5HIAA value in the presence of normal 5-
hydroxytryptophan and tryptophan levels. The values for the
catecholamine pathway metabolites L-dopa, 3-O-methyldopa and
homovanillic acid (HVA), as well as the pterin metabolites (biopterin,
neopterin) and 5-methyltetrahydrofolate were normal (not shown).
The low 5HIAA value explained the elevated HVA/5HIAA ratio. A
twenty-four hours urinary collection on a diet excluding food
products with a high tryptophan content detected a low daily
5HIAA urinary excretion of 5 μmol (reference range 10–50 μmol/
day), which normalized to a normal daily excretion of 71 μmol after an
oral load of 5-hydroxytryptophan at 1 mg/kg body weight/day
(divided in three daily doses).
A slowly titrating oral dose in the patient was started up to a ﬁnal
daily dose of 7 mg/kg 5-hydroxytryptophan, and from the age of
5½years we reduced 5-hydroxytryptophan to 5 mg/kg and added
1 mg/kg carbidopa, divided into three equal doses. Clinical recovery
resulted ﬁrst in disappearance of hypotonia and ataxia, later followed
by slow disappearance of autistic features and amelioration of speech
and cognitive skills. However, speech delay persisted. Follow-up CSF
analysis during oral substitution with 5-hydroxytryptophan alone
(7 mg/kg/day) did not show normalization of CSF 5HIAA but addition
of carbidopa showed normalization of 5HIAA values and the HVA/
5HIAA ratio (see Table 1).
The isolated low serotonin metabolite 5HIAA in the CSF prompted
us to investigate by a candidate gene approach factors that might be
speciﬁcally involved in the metabolism or transport of serotonin.
Among them,we tested for alterations in the TPH1 and 2 genes, as well
as the gene encoding the GTP-cyclohydrolase I feedback regulatory
protein (GFRP, GCHFR gene). Whereas both tetrahydrobiopterin-
dependent TPH isoforms are rate limiting enzymes for serotonin
biosynthesis [22,23], the GFRP was reported to be expressed in
speciﬁc brain tissues and potentially be involved in the regulation of
tetrahydrobiopterin biosynthesis in serotonin (but not dopamine)
neurons [24]. Only wild-type sequences were found for the TPH1/2
and GCHFR genes (not shown).
Upon sequencing the coding exons plus exon–intron boundaries of
the SERT transporter SLC6A4 gene, we found in exon 3 at amino-acid
codon 56 the heterozygous nucleotide variant c.167GNC, leading to a
glycine to alanine exchange (also known as rs6355; see Fig. 1). The
heterozygous SLC6A4 Gly56Ala allele was inherited from his mother.
Besides this well known mutant allele, we should mention that
additionally we found a homozygous SNP in the non-coding exon 2,
c.−185CNA (rs6354).
The SLC6A4 gene promoter sequence 5-HTTLPR showed the
homozygous L/L variant for the patient, whereas his mother had the
L/S and the father had the L/L variants (Fig. 2A). As indicated in theTable 1
CSF ﬁndings in patient CM with the heterozygous SLC6A4 Gly56Ala mutation.
Patient Age (yrs) 5HIAA (nmol/l) HVA (nm
CM 3.7 102 372
5.2 107 334
5.9 186 367
Ref. 2–4 202 (105–299) 603 (211
5–10 133 (88–178) 523 (144
Reference values and ranges see also [21].Introduction, the L/L variant should lead to a lower serotonin
concentration in the synaptic cleft than the other two variants [13].
As a ﬁnal genetic alteration potentially inﬂuencing the activity of
SERT, we analyzed the STin2 VNTR region in intron 2, and found the 9/10
variant for the patient, 10/12 for his mother and 9/10 for his father
(Fig. 2B).
Themutations and variants found in the SLC6A4 gene in this family
are summarized in Table 2. In summary, a patient with atypical autism
was found to carry the heterozygous Gly56Ala allele in the SLC6A4
gene and exhibited low 5HIAA in CSF. Clinical improvement and
normalization of serotonin turnover in the brain was found upon
therapeutic intervention with 5-hydroxytryptophan/carbidopa. The
implications of these ﬁndings will be discussed below.
4. Discussion
Allelic heterogeneity at the serotonin transporter gene locus
(SLC6A4) was reported to confer susceptibility to autism and rigid–
compulsive behavior. The patient we report here has a history of
impaired motor and speech development and atypical autism or PDD-
NOS. Moreover, we found isolated low 5HIAA in CSF indicative for low
extracellular serotonin levels in brain. As documented in previousol/l) HVA/5HIAA Remarks
3.6 No treatment
3.1 7 mg/kg/day 5-hydroxytryptophan
2.0 5 mg/kg/day 5-hydroxytryptophan
and 1 mg/kg/day carbidopa
–871) 1.5–3.5
–801) 1.5–3.5
Fig. 2. SLC6A4 5-HTTLPR promoter and gene variants. (A) Ampliﬁcation of 5-HTTLPR
promoter variants. The PCR products at 523 bp and 479 bp indicate the present of the L
(long) variant and the S (short) variant with a 44 bp deletion, respectively. (B) Analysis
of the STin2 VNTR variants by PCR from patient CM and his parents. Ampliﬁcation of the
VNTR region in intron 2 (STin2) reveals the number of repetitive elements: 345 bp (9
copies), 360 bp (10 copies) or 390 bp (12 copies).
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would be expected to lead to increased uptake and a serotonin overload
within platelets, where the protein mutant is expressed. Furthermore,
at the brain level, the consequent intracellular serotonin overload
among SERT Gly56Ala heterozygous or homozygous subjects would be
expected to increase serotonin re-uptake into pre-synaptic vesicles.
Serotonin accumulation within pre-synaptic cells (or neighboring
neurons and/or astrocytes) might predispose to secondary diminished
serotonin metabolism and degradation by MAO enzymes. Evidence
from functional neuro-imaging studies in autism has indicated low
serotonin production within the brain between 2 and 5 years, while
dietary tryptophan depletion aggravated the autistic behavior. How-
ever, the exact mechanism underlying these observations of dimin-
ished serotonin production in the brain has not been identiﬁed.
Moreover, several authors have reported no difference for 5HIAA in CSF
measured in autistic patients (for an overview see [17]), which is in
contradiction to our routine determination of 5HIAA in CSF in patients
with autistic disorders where we ﬁnd a signiﬁcant percentage of
patientswith low5HIAA (unpublished observation). On the other hand,
several other laboratories reported recently on isolated low 5HIAA level
in CSF from patients with neurological disorders and neuro-psychiatricTable 2
Polymorphisms and mutations in the SLC6A4 gene.
Subject 5-HTTLPR STin2 VNTR rs6355 (exon 3)
Patient CM L/L 9/10 Heterozygous c.167GNC (p.Gly56Ala)
Mother L/S 10/12 Heterozygous c.167GNC (p.Gly56Ala)
Father L/L 9/10 Wild-type c.167G (p.Gly56)
Mutation designation is based on transcript ID: ENST00000394821 (Ensemble
database) with 15 exons. The transcript length is 6335 bps, and the translation
length is 672 residues. The numbering starts with 1 at A at the ATG-start codon.disturbances, including ASD (without identifying an underlying genetic
cause) [25].
Toﬁnd a genetic basis that could potentially explain the isolated low
serotonin in the CNS (determined indirectly by the lowered 5HIAA
concentration in CSF), we performed DNA mutation screening not only
for the SERT transporter, encoded by the SLC6A4 gene, but also for other
candidate genes that are directly involved in serotonin metabolism,
such as TPH1, TPH2, and GCHFR. In addition to the described genetic
variations in SLC6A4, there are other gene variants that may have an
additional effect or modest inﬂuence on autism risk. These include de
novo copy number variations [26], serotonergic receptor single
nucleotide polymorphisms such as in the HTR3A gene [27], and also
other genetic variants (for a recent overview see [28]). Since the impact
of these genetic variations remains unclear or inconclusive, we did not
collect these data. Our patient with atypical autism carrying the
Gly56Ala/wt genotype in combination with the L/L variant of the
SLC6A4 promoter sequence is thought to have increased expression of
both, the normal and mutated allele. We hypothesize that this will
predispose to elevated serotonin re-uptake from synaptic clefts, and
may be the deciding factor for the autistic phenotype. Furthermore,
while the combination of the Ala56 allele with STin2 VNTR remains
unclear regarding SERT function, we speculate that the L/S variant, in
combination with the Gly56Ala/wt genotype, is the reason why the
mother is a non-affected carrier. In addition, we have investigated the
SLC6A4 gene for the Gly56Ala alteration in our current collection of
samples from 137 patients with autistic disorder and identiﬁed the
heterozygous situation in at least ﬁve other subjects. Although we do
not know at this point the 5HIAA status in CSF for all ﬁve patients, at
least one has lowered 5HIAA, indicating that low serotonin together
with the SERT mutation may be more common in autism spectrum
disorder (unpublished observation).
Physiologically, the low CSF 5HIAA levels and diminished urinary
5HIAA excretion in our patient indicate low serotonin turnover. The
normalization of urinary 5HIAA excretion after a 5-hydroxytrypto-
phan loading dose in our patient suggested diminished function of the
ﬁrst rate-limiting enzyme of serotonin synthesis, being the peripheral
enzyme TPH1 converting tryptophan to 5-hydroxytryptophan. Like-
wise, the low 5HIAA value in spinal ﬂuid with normalization after
treatment by 5-hydroxytryptophan and carbidopa might also suggest
low activity by neuronal TPH2. We speculate that an increased
serotonin re-uptake by the protein mutant (Gly56Ala) of the
serotonin transporters results in an initial overload of serotonin
within neuronal tissue and might thus lead to indirect inhibition of
serotonin synthesis with consequent reduction of the activity of the
rate-limiting enzyme TPH2 (Fig. 3). Further investigation on the
mechanisms explaining this indirect inhibition upon neuronal and
peripheral TPH1 enzymeswarrants subsequent studies. An alternative
hypothesis is that the increased serotonin re-uptake initially leads to
serotonin accumulation into pre-synaptic cytoplasm with increased
transport into vesicles by the vesicular mono-amine transporter
(VMAT) and increased degradation by aldehyde dehydrogenase and
MAO enzymes. The subsequent enhanced catabolism might in time
predispose to overall pre-synaptic serotonin depletion and low
serotonin release. In transgenic mice, over-expressing the SERT
protein low intraneuronal levels of serotonin and diminished release
have been documented [29]. However, more complex adaptive
changes mediated by up-regulation of pre-synaptic serotonin auto
receptors in the brainstem raphe nuclei (5-HT1A) or at pre-synaptic
nerve terminals (5-HT1B/1D) might also provide an explanation for
low serotoninergic transmission at these synapses carrying the up-
regulated SERT protein [14,30].
In conclusion, our ﬁndings in a patient with speech delay and
atypical autism associated with gain of function of the SLC6A4
serotonin transporter gene (Gly56Ala/wt) suggested a ﬁnal stage of
serotonin depletion or reduced serotonin turnover. Moreover, the
important clinical and biochemical response following treatment by
Fig. 3. Possible effects of increased SERT activity. The left side shows normal serotonin synthesis and release followed by serotonin transporter (SERT) mediated re-uptake into the
pre-synaptic terminal where either recycling into vesicles or catabolism to 5HIAA byMAO enzymes takes place. On the right, our hypothesis is depicted with low serotonin turnover
in the presence of high expression of SERT due to presence of the L/L promoter variant plus gain of function by the SERT 56Ala mutant transporter. The consequent overall increased
re-uptake may lead to serotonin accumulation within pre-synaptic terminals (indicated with a question mark). The presence of high intra-neuronal serotonin concentrations is
speculated to predispose to secondary diminished serotonin turnover by up to three different mechanisms: (a) indirect inhibition of the rate-limiting serotonin producing enzyme
TPH2, (b) increased recycling and degradation of serotonin to 5HIAA resulting in pre-synaptic serotonin depletion, and (c) up-regulation of 5-HT1A autoreceptors within brainstem
raphe nuclei (not shown in the ﬁgure) and 5-HT1B/1D autoreceptors at pre-synaptic nerve terminals in response to low serotonin concentration within the synaptic space. The up-
regulated 5-HT1A and 5-HT1B/1D receptors will diminish axonal excitability and subsequent serotonin release. Abbreviations: SERT: serotonin transporter; Trp: L-Tryptophan; 5-
OH-Trp: 5-hydroxytryptophan; TPH2: brain tryptophan hydroxylase 2; 5-HT1A: serotonin 1A autoreceptor in raphe nuclei; 5-HT1B/1D: serotonin autoreceptors in nerve terminals;
5HIAA: 5-hydroxyindoleacetic acid.
372 D. Adamsen et al. / Molecular Genetics and Metabolism 102 (2011) 368–3735-hydroxytryptophan and carbidopa supports our speculations about
one possible pathophysiology of autism.
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